# US 8,277,808 B2 · Mucosal vascular addressins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,808 B2
- Document ID: US8277808B2
- Status: Granted
- Kind: B2
- Application number: 11/732,400
- Filed: 2007-04-03
- Published: 2007-08-02
- Granted: 2012-10-02
- Earliest claimed: 1995-09-01
- Assignees: Millennium Pharmaceuticals, Inc.
- Inventors: Michael J. Briskin
- Web page: https://patentgrep.com/patent/US8277808B2

## CPC

- C07K 14/70503: {Immunoglobulin superfamily}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2839: {against the integrin superfamily}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y10S 530/866: involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to isolated antibodies and antigen-binding fragments thereof that bind naturally occurring human MAdCAM, wherein said naturally occurring human MAdCAM comprises a polypeptide with at least 90% sequence identity to SEQ ID NO:2 or SEQ ID NO:4, said naturally occurring human MAdCAM binds α4β7, and wherein said isolated antibodies and antigen-binding fragments thereof inhibit binding of said naturally occurring human MAdCAM to human α4β7, and wherein said antibody inhibits adhesion of RPMI 8866 cells to cells that express said human MAdCAM.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof that binds naturally occurring human MAdCAM, wherein said naturally occurring human MAdCAM comprises a polypeptide with at least 90% sequence identity to SEQ ID NO:2 or SEQ ID NO:4, said naturally occurring human MAdCAM binds α4β7, and wherein said isolated antibody or antigen-binding fragment thereof inhibits binding of said naturally occurring human MAdCAM to human α4β7, and wherein said antibody inhibits adhesion of RPMI 8866 cells to cells that express said human MAdCAM.

### Claim 2 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein said human MAdCAM comprises amino acids 19-406 of SEQ ID NO:2.

### Claim 3 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein said human MAdCAM comprises amino acids 19-382 of SEQ ID NO:4.

### Claim 4 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein said antibody or antigen-binding fragment selectively binds to the extracellular region of human MAdCAM.

### Claim 5 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein said antibody or antigen-binding fragment selectively binds amino acids 19-225 of SEQ ID NO:2.

### Claim 6 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein said antibody or antigen-binding fragment selectively binds amino acids 19-225 of SEQ ID NO:4.

### Claim 7 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein said antibody inhibits α4β7-dependent adhesion.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and a physiologically acceptable carrier.

### Claim 9 (depends on 1)

An isolated cell that produces an antibody or antigen-binding fragment of claim 1.

### Claim 10 (depends on 1)

A method of treating an inflammatory disease of mucosal tissue, comprising administering an effective amount of the antibody or antigen-binding fragment of claim 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein said inflammatory disease is inflammatory bowel disease.

### Claim 12 (depends on 1)

A method of detecting naturally occurring human MAdCAM in a sample, comprising contacting said sample with an antibody or antigen-binding fragment of claim 1, and detecting antibody-MAdCAM or antigen-binding fragment-MAdCAM complexes which are formed.

### Claim 13 (depends on 1)

The isolated antibody of claim 1, wherein said human MAdCAM comprises SEQ ID NO:17.

### Claim 14 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein said antibody or antigen-binding fragment does not inhibit binding of RAMOS cells to cells expressing VCAM-1.
